Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
Can Venous Lactate Predict the Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients Without Hemodynamic Shock in Emergency Department?
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Bangkok
-
Patumwan, Bangkok, Thailand, 11130
- Emergency Medicine Unit, King Chulalongkorn Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 to 65 years
- Confirmed or suspected diagnoses of acute infections (within 7 days)
- Major infections (e.g. Acute pyelonephritis, Acute bronchitis/pneumonia, Acute hepatobiliary tract infections, intrabdominal abscesses, meningitis and other central nervous system infections, soft tissue infections involving more than 10 square centimeters of the skin surface or deeper down beyond the dermis, significant tropical infections; dengue fever, leptospirosis, typhus fevers, or high fever from any infectious sources)
- Systolic blood pressure more than 90 mmHg at presentation
- Mean arterial pressure more than 70 mmHg at presentation
Exclusion Criteria:
- Duplicated cases that have participated in this study during the study period
- Overt organ hypoperfusion (e.g. cold, clammy or mottling skin, altered mental status; Glasgow Coma Scale equal to or less than 12 or decrease > 1 compared with the baseline)
- Pulse oximetry equal to or less than 90% at ambient air
- received intravenous fluid more than 10 ml/kg prior to the venous blood sampling
- received intravenous antibiotics for more than 1 hours prior to the venous blood sampling
- Minor infections (e.g. uncomplicated upper respiratory tract infections, gastroenteritis, minor skin infections)
- currently taking antiretroviral drugs
- having or suspicious of having seizures in the past 72 hours
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
High lactate
Initial venous lactate level equal to or more than 2.0 mmol/L
|
|
Low lactate
Initial venous lactate level less than 2.0 mmol/L
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator
Time Frame: 72 hours after venous lactate measurement
|
Proportion of the patients in each cohort who require vasopressor/mechanical ventilator to maintain their vital signs in the next 72 hours after venous lactate measurement.
|
72 hours after venous lactate measurement
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause Mortality Rates
Time Frame: 30 days after the day of presentation to the emergency department
|
Electronic database retrieval of in- and outpatient clinical records together with telephone follow-ups to the patients or their contact personnel are employed to every case in the next 30 days after the day of presentation to the emergency department to identify the deceased cases.
All-cause mortality rates of each cohort will be compared by the survival analysis.
|
30 days after the day of presentation to the emergency department
|
|
Hospital Length of Stay
Time Frame: Patients will be followed for the duration of hospital stay, an expected average of 7 days
|
Numbers of days spent in the hospital since the emergency department arrival to hospital discharge
|
Patients will be followed for the duration of hospital stay, an expected average of 7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Khrongwong Musikatavorn, MD, Department of Medicine, Facalty of medicine, Chulalongkorn University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 793/2012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.